ArticleAmerican journal of cancer research2025
Comparative effectiveness of perioperative strategies for resectable gastric and gastroesophageal junction cancer: a Bayesian network meta-analysis.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Optimal neoadjuvant regimens for locally advanced gastric and gastroesophageal junction cancer: a systematic review and bayesian network meta-analysis.World journal of surgical oncology · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perioperative strategies for resectable gastric and gastroesophageal junction (GEJ) adenocarcinomas are continuously evolving, with recent regimens, particularly those incorporating immunotherapy, showing promising results, although their comparative efficacy remains uncertain. We conducted a Bayesian network meta-analysis of randomized controlled trials (RCTs) published between January 2004 and March 2025 that compared perioperative treatments involving chemotherapy, radiotherapy, immunotherapy, or targeted agents. Five outcomes were analyzed: overall survival (OS), progression-free survival (PFS), R0 resection, pathological complete response (pCR), and major pathological response (MPR). A Bayesian random-effects model was applied to estimate hazard ratios (HRs) and odds ratios (ORs), and surface under the cumulative ranking curve (SUCRA) values were used for treatment ranking. A total of 25 RCTs involving 11,317 patients were included. Neo/Peri DOS/DOX, comprising neoadjuvant or perioperative docetaxel-oxaliplatin-S-1 (DOS) or docetaxel-oxaliplatin-capecitabine (DOX), ranked highest for OS and PFS, showing significant survival benefits over both surgery alone and adjuvant chemotherapy. Regimens combining perioperative chemotherapy with PD-1/PD-L1 inhibitors (Neo/Peri CT+PD1/PDL1) achieved the greatest improvement in pCR and MPR, although their survival benefit was limited to comparisons with surgery alone. None of the regimens significantly improved R0 resection. The findings were robust across sensitivity analyses, with no major inconsistencies detected. In conclusion, DOS/DOX demonstrated superior survival outcomes and may represent a leading perioperative option, while PD-1/PD-L1-based combinations improved early pathological responses but require further validation with mature survival data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.